11
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Growth hormone activates PI3K/Akt signaling and inhibits ROS accumulation and apoptosis in granulosa cells of patients with polycystic ovary syndrome

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          It is reported that growth hormone (GH) can alleviate oxidative stress (OS) induced apoptosis in some types of cells by activating the PI3K/Akt signaling pathway. This study investigated the role and underlying mechanism of GH in OS and apoptosis in granulosa cells (GCs) of patients with polycystic ovary syndrome (PCOS).

          Methods

          Primary GCs were collected from patients with and without PCOS (controls, n = 32) during oocyte retrieval. The patients with PCOS were randomly assigned to take GH treatment (PCOS-GH, n = 30) or without GH treatment (PCOS-C, n = 31). Reactive oxygen species (ROS) level was determined by spectrophotometry and fluorescence microscopy. GC apoptosis and mitochondrial membrane potential (MMP) were detected by Annexin V-FITC/PI double-staining and JC-1 staining, respectively (flow cytometry). The expression of apoptosis-related genes and proteins involved in PI3K/Akt signaling was determined by quantitative reverse-transcription polymerase chain reaction and western blotting, while active caspase-9 and caspase-3 levels of GCs were determined by enzyme-linked immunosorbent assay.

          Results

          Our study found that in GCs of the PCOS-GH group, the ROS levels and apoptotic rates were significantly decreased, whereas MMP was significantly increased when compared to those in the PCOS-C group ( P < 0.05). The mRNA levels of FOXO1, Bax, caspase-9, and caspase-3 were significantly decreased, whereas Bcl-2 was increased in GCs of the PCOS-GH group than those in the PCOS-C group ( P < 0.05). The protein levels of FOXO1, Bax, cleaved caspase-9/caspase-9 and cleaved caspase-3/caspase-3 were decreased, whereas p-PI3K/PI3K, p-Akt/Akt, p-FOXO1 and Bcl-2 were increased in GCs of the PCOS-GH group, compared with those in the PCOS-C group ( P < 0.05).

          Conclusion

          OS induced apoptosis and downregulated the PI3K/Akt signaling pathway in patients with PCOS. GH could alleviate apoptosis and activate the PI3K/Akt signaling pathway.

          Clinical trial registration number

          Chinese Clinical Trial Registry. ChiCTR1800019437. Prospectively registered on October 20, 2018.

          Related collections

          Most cited references37

          • Record: found
          • Abstract: found
          • Article: not found

          Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)

          (2004)
          Since the 1990 NIH-sponsored conference on polycystic ovary syndrome (PCOS), it has become appreciated that the syndrome encompasses a broader spectrum of signs and symptoms of ovarian dysfunction than those defined by the original diagnostic criteria. The 2003 Rotterdam consensus workshop concluded that PCOS is a syndrome of ovarian dysfunction along with the cardinal features hyperandrogenism and polycystic ovary (PCO) morphology. PCOS remains a syndrome and, as such, no single diagnostic criterion (such as hyperandrogenism or PCO) is sufficient for clinical diagnosis. Its clinical manifestations may include: menstrual irregularities, signs of androgen excess, and obesity. Insulin resistance and elevated serum LH levels are also common features in PCOS. PCOS is associated with an increased risk of type 2 diabetes and cardiovascular events.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Therapeutic potential of resveratrol: the in vivo evidence.

            Resveratrol, a constituent of red wine, has long been suspected to have cardioprotective effects. Interest in this compound has been renewed in recent years, first from its identification as a chemopreventive agent for skin cancer, and subsequently from reports that it activates sirtuin deacetylases and extends the lifespans of lower organisms. Despite scepticism concerning its bioavailability, a growing body of in vivo evidence indicates that resveratrol has protective effects in rodent models of stress and disease. Here, we provide a comprehensive and critical review of the in vivo data on resveratrol, and consider its potential as a therapeutic for humans.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Clinical assessment of body hair growth in women.

                Bookmark

                Author and article information

                Contributors
                Weihuang64@163.com
                Journal
                Reprod Biol Endocrinol
                Reprod Biol Endocrinol
                Reproductive Biology and Endocrinology : RB&E
                BioMed Central (London )
                1477-7827
                7 December 2020
                7 December 2020
                2020
                : 18
                : 121
                Affiliations
                [1 ]GRID grid.461863.e, ISNI 0000 0004 1757 9397, Department of Obstetrics and Gynecology, , West China Second University Hospital of Sichuan University, ; Chengdu, Sichuan People’s Republic of China
                [2 ]GRID grid.419897.a, ISNI 0000 0004 0369 313X, Key Laboratory of Birth Defects and Related Diseases of Women and Children, , Ministry of Education, ; Chengdu, Sichuan People’s Republic of China
                [3 ]GRID grid.413856.d, ISNI 0000 0004 1799 3643, Reproductive Medicine Center, Sichuan Provincial Women’s and Children’s Hospital, , The Affiliated Women’s and children’s Hospital of Chengdu Medical College, ; Chengdu, Sichuan People’s Republic of China
                [4 ]GRID grid.419897.a, ISNI 0000 0004 0369 313X, Laboratory of Genetic Disease and Perinatal Medicine, Key Laboratory of Birth Defects and Related Diseases of Women and Children, , Ministry of Education, ; Chengdu, Sichuan People’s Republic of China
                [5 ]GRID grid.461863.e, ISNI 0000 0004 1757 9397, Department of Reproductive Medicine, , West China Second University Hospital of Sichuan University, ; #1416 Chenglong Road, JinJiang District, Chengdu, Sichuan 610041 People’s Republic of China
                Author information
                http://orcid.org/0000-0001-9306-588X
                Article
                677
                10.1186/s12958-020-00677-x
                7720521
                33287836
                dbf880a2-85e9-495a-b48f-7c78ca1d495c
                © The Author(s) 2020

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

                History
                : 12 September 2020
                : 20 November 2020
                Funding
                Funded by: the Key Research and Development project of Science and Technology Bureau of Sichuan
                Award ID: 2019YF S0406
                Award Recipient :
                Funded by: the Scientific Research Project of Sichuan Provincial Health Commission
                Award ID: 20PJ123
                Award Recipient :
                Funded by: the Technology Innovation Project of Science and Technology Bureau of Chengdu
                Award ID: 2018-YF05-00247-SN
                Award Recipient :
                Funded by: the Scientific Research Project of Sichuan Medical Association
                Award ID: S17060
                Award Recipient :
                Categories
                Research
                Custom metadata
                © The Author(s) 2020

                Human biology
                polycystic ovary syndrome,growth hormone,reactive oxygen species,apoptosis,pi3k/akt signaling

                Comments

                Comment on this article